Urinary MicroRNA-21 for Prostate Cancer Detection Using a Silver Nanoparticle Sensor
Author Information
Author(s): Pang See-Tong, Chiou Yueh-Er, Lim Jasmine, Zhang Yi-Chun, Zeng Wen-Zhen, Ong Teng Aik, Weng Wen-Hui
Primary Institution: Chang Gung Memorial Hospital
Hypothesis
Can urinary miR-21 levels be effectively detected using a silver nanoparticle sensor for prostate cancer diagnosis?
Conclusion
The urinary miR-21 biosensor can effectively distinguish prostate cancer patients from those with benign prostatic hypertrophy and healthy subjects.
Supporting Evidence
- The biosensor showed a sensitivity of up to 100 fM.
- miR-21 levels were significantly lower in patients at 3 months post-surgery compared to pre-surgery.
- Significant differences in miR-21 levels were found between healthy subjects and patients with prostate cancer or benign prostatic hypertrophy.
Takeaway
This study shows that a special sensor can find a tiny molecule in urine that helps doctors tell if someone has prostate cancer.
Methodology
The study used a silver nanoparticle-based biosensor to detect miR-21 levels in urine samples from prostate cancer patients, benign prostatic hypertrophy patients, and healthy controls, validated by qRT-PCR.
Limitations
The study excluded patients with other cancers and serious diseases, which may limit the generalizability of the findings.
Participant Demographics
The study included 10 patients with prostate cancer, 3 patients with benign prostatic hypertrophy, and 5 healthy subjects.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website